Study Overview: This clinical trial is for people with a type of pancreatic cancer called unresectable pancreatic adenocarcinoma (uPDAC). The study is testing a combination of drugs: Gemcitabine, Nab-paclitazel, and possibly Pitavastatin, to find the best dose for future studies. Participants must already be receiving Gemcitabine.

Eligibility: To join, you must be at least 18 years old, have confirmed pancreatic cancer, and be in stable condition with Gemcitabine treatment. You should have good organ function, no recent major surgeries, and not be pregnant or breastfeeding. Certain other illnesses or conditions may exclude you from participating.

• The study involves taking the study drugs and regular medical check-ups.
• Participants should expect to follow the study protocol, which may include discontinuing other medications like statins.
• Potential risks include side effects from the study drugs, similar to those experienced with standard cancer treatments.